CRMD CorMedix Inc

0.47
+0.0218  (5%)
Previous Close 0.45
Open 0.45
Price To book 1.65
Market Cap 19.17M
Shares 40,624,000
Volume 1,214,779
Short Ratio 7.26
Av. Daily Volume 394,811

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be completed 2Q 2018. Data due end of 2018 with interim analysis possibly due 4Q 2017.
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 to be initiated pending funding.
Neutrolin - LOCK-IT 200
Oncology patients on Total Parental Nutrition (TPN)

Latest News

  1. CorMedix Inc. Appoints Mehmood Khan, M.D. and Steven Lefkowitz to its Board of Directors
  2. Implied Volatility Surging for CorMedix (CRMD) Stock Options
  3. ETFs with exposure to CorMedix, Inc. : June 16, 2017
  4. CorMedix Inc. to Showcase Its Taurolidine-Based Development Pipeline at Research and Development Day
  5. CorMedix Inc. Announces Changes to Board of Directors
  6. ETFs with exposure to CorMedix, Inc. : May 26, 2017
  7. INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CorMedix, Inc.
  8. CorMedix, Inc. :CRMD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  9. CorMedix Inc. Reports First Quarter Financial Results and Provides Business Update
  10. CorMedix Inc. Demonstrates Sensitivity of Emerging Global Health Threat Candida auris to Taurolidine
  11. CorMedix Inc. to Report First Quarter 2017 Financial Results and Provide Business Update
  12. CorMedix Inc. Announces Closing of Public Offering of Common Stock and Warrants and Underwriter's Exercise in Full of Over-Allotment Option
  13. CorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million
  14. CorMedix Inc. Announces $10 Million Underwritten Public Offering
  15. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CorMedix, Inc.
  16. CorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial
  17. CorMedix Inc. Secures First European Commercial Collaboration for Neutrolin(R)
  18. ETFs with exposure to CorMedix, Inc. : April 10, 2017